Kallmann syndrome

A genetic condition characterized by delayed or absent puberty and an impaired sense of smell

Kallmann syndrome is a rare genetic disorder that is characterized by a combination of hypogonadotropic hypogonadism and anosmia or hyposmia. It is a form of hypogonadotropic hypogonadism where the production of gonadotropin-releasing hormone (GnRH) is deficient, leading to a lack of sexual development and a diminished or absent sense of smell.

Pathophysiology

Kallmann syndrome is caused by a failure in the development of the olfactory bulbs and the migration of GnRH-producing neurons during embryonic development. This results in the absence or underdevelopment of the olfactory bulbs and a deficiency in GnRH, which is crucial for the stimulation of the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones are essential for the normal function of the gonads and the onset of puberty.

Genetics

Kallmann syndrome can be inherited in an X-linked recessive, autosomal dominant, or autosomal recessive manner. Several genes have been implicated in the condition, including:

• KAL1 on the X chromosome, which is responsible for the X-linked form of the disorder.
• FGFR1 (also known as KAL2), which can cause an autosomal dominant form.
• PROKR2 and PROK2, which are associated with autosomal recessive forms.

Clinical Features

The primary clinical features of Kallmann syndrome include:

• Delayed or absent puberty
• Anosmia or hyposmia (reduced or absent sense of smell)
• Infertility due to hypogonadism

Additional features may include:

• Cleft lip or palate
• Hearing loss
• Renal agenesis (absence of one kidney)
• Mirror movements (bimanual synkinesis)

Diagnosis

Diagnosis of Kallmann syndrome is based on clinical evaluation, family history, and laboratory tests. Key diagnostic criteria include:

• Low levels of sex steroids (testosterone in males, estrogen in females)
• Low or normal levels of LH and FSH
• MRI imaging may reveal underdeveloped or absent olfactory bulbs
• Genetic testing can confirm mutations in known associated genes

Treatment

Treatment for Kallmann syndrome focuses on hormone replacement therapy to induce and maintain secondary sexual characteristics and fertility. Options include:

• Testosterone replacement therapy for males
• Estrogen and progesterone therapy for females
• Pulsatile GnRH therapy or gonadotropin injections to stimulate fertility

Prognosis

With appropriate treatment, individuals with Kallmann syndrome can achieve normal sexual development and fertility. However, the sense of smell typically does not improve with treatment.

Related pages

• Hypogonadotropic hypogonadism
• Anosmia
• Gonadotropin-releasing hormone
• Luteinizing hormone
• Follicle-stimulating hormone